Johnson & Johnson (NYSE: JNJ) today announced one-year results from the Phase 3 FUZION study showing TREMFYA® (guselkumab) ...

New TREMFYA® (guselkumab) 3-year as-observed data show clinical remission rates of up to 94% (172/183 patients) and endoscopic remission rates of up to 52% (89/172 patients) in adults with moderate to ...

The scramble to power AI data centers with reactors now has a Moscow angle, which puts sanctions and export-control risk squarely into nuclear infrastructure deals.

Researchers in Slovakia benchmarked five lossless compression algorithms directly on an STM32 microcontroller, revealing ...

Anthropic cut Claude Code first-token latency from 4.07s to 1.33s using gzip compression and earlier cloud session startup.

UniConverter 18 expands its image and video enhancement capabilities, helping users improve visual quality with less manual ...

New research presented at ENGAGE26 explores how AI tools, ABI testing, pressure mapping, and advanced wound treatments can ...

Persistent Systems (NSE:PERSISTENT) presented its Q2 FY27 investor slides on October 15, 2026, highlighting another quarter ...

Nordex Electrolyzers unveiled the NX2500, a 2.5 MW pressurized alkaline electrolyzer fully designed and tested in Navarra, ...

USA Compression Partners, LP (TXSE: USAC) (“USA Compression”) today announced a cash distribution of $0.525 per common unit ($2.10 on an annualized basis) for the third quarter of 2026. The ...